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ABSTRACT 
Lanosterol 14 α-demethylase (CYP51) is a key protein involved in ergosterol biosynthesis of Candida albicans and a crucial target for ergosterol 
synthesis inhibition. However, in the last two decades drug resistance is reported under clinical situations to most of the prescribed antifungal drugs like 
azole group of drugs. In this study, molecular docking of sixty plant molecules with Lanosterol 14 α-demethylase protein has been done. The homology 
modeling tool PHYRE2 was used to predict the structure of Lanosterol 14 α-demethylase. Predicted structure was used for docking studies with sixty 
plant molecules by using Autodock 1.5.6 cr2™. Among the sixty plant molecules, forty-seven were found to form hydrogen bond and the rest of the plant 
molecules did not form a hydrogen bond with Lanosterol 14 α-demethylase. Docking study of a library of sixty molecules revealed that 48 plant 
molecules showed an excellent and good binding affinity with predicted protein model Lanosterol 14 α-demethylase of Candida albicans. The binding 
residue comparison of docked molecules with that of Ketoconazole revealed, fourteen molecules have similar binding residue. These fourteen molecules 
may have a similar mode of action as that of Ketoconazole. These molecules should be screened and used to discover new antifungal therapeutic drugs. 
Keywords: Lanosterol 14 α-demethylase, Phytochemicals, Molecular docking, Candida albicans, Ergosterol synthesis 
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
DOI: http://dx.doi.org/10.22159/ijap.2020.v12s4.40100. Journal homepage: https://innovareacademics.in/journals/index.php/ijap 
 
INTRODUCTION  
The prevalence of opportunistic fungal infections has blown up in the 
couple of years [1]. 1.5 to 2 million deaths occur every year due to fungal 
infections in immunocompromised patients such as those suffering from 
autoimmune diseases, AIDS, burns and chemo or radiotherapy [2]. One 
of the most commonly used drugs for the prevention of Candidiasis is 
Fluconazole, a member of the azole family. Its target is an essential 
enzyme, Lanosterol 14 α-demethylase a member of the cytochrome 
P450 superfamily. This is a heme thiolate enzyme which converts 
lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol [3]. The 
activity of azole drugs is attributed to the co-ordinate binding of the 
heterocyclic nitrogen atom (N-3 of imidazole and N-4 of triazole) to the 
heme iron atom in the binding site of CYP51 enzyme. Inhibition of 
CYP51, and depletion of ergosterol coupled with the accumulation of 14-
methyl sterols results in impaired fungal growth [4]. The vital role of 
CYP51 in fungal metabolism makes it an ideal target for antifungal drug 
design [5]. Numerous classes of the drugs have been developed which 
target the ergosterol biosynthetic pathway [6, 7].  
To treat fungal infection, there are five classes of drugs. These are 
Polyenes, azoles, echinocandins, allylamines and fluoropyrimidines. In 
addition to drug resistance, acute and chronic side effects, less clinical 
efficiency and effect on non-target cells are the hitch of the existing 
drugs and therefore, researchers around the world are in the search 
for novel and efficient antifungal drugs [8]. Resistance towards the 
drugs and side effects clearly indicates that there is a need for 
development of new drugs. Researchers has previously indicated that 
the structurally and functionally essential regions, such as the heme 
group, the hydrophilic H-bonding region, the narrow hydrophobic 
cleft-substrate access channel 2 (FG loop), and the active site could be 
good targets for antifungal drugs. The binding mode of azoles with 
lanosterol 14 α-demethylase protein of Candida albicans CYP51 has 
been investigated through molecular docking [9, 10]. The molecular 
modeling can accelerate the discovery of novel antifungal agents 
through the exploitation of structural in order of fungal CYP51s [11]. 
In the present work, we have screened a library of sixty molecules 
for molecular docking with the predicted structure of lanosterol 
14 α-demethylase protein of Candida albicans to investigate their 
binding affinity in search of Phytochemicals as potent antifungal 
drugs.  
MATERIALS AND METHODS 
Homology modeling of Lanosterol 14 α-demethylase (CYP51) 
Primary sequence of Lanosterol 14 α-demethylase (CYP51) was 
retrieved in FASTA format from the Uniprot public domain protein 
database (Uniprot accession no. P10613). Retrieved sequence was 
submitted to the Phyre2 homology modeling program for modeling 
of the three-dimensional structure of the protein [12]. Tertiary 
structure was predicted and Validation of tertiary structure was 
done by Procheck [13]. Tertiary structure of Lanosterol 14 α-
demethylase (CYP51) was used for docking studies [14].  
Protein structure preparation 
The Autodock Tools package version 1.5.6 rc 2 was employed to 
generate the docking input files. 
All the nonpolar hydrogens were merged and the water molecules 
were removed. For Docking, a grid spacing of 0.375 Å and 60×60×60 
number of points was used. Before docking all water molecules were 
removed from the protein structure, followed by addition of Hydrogen 
atoms to receptor and merging non-polar hydrogens. Modeled three 
dimensional structure of Lanosterol 14 α-demethylase and the 
structure of each ligand were converted to PDBQT format [14, 15].  
Ligand structure preparation 
The structures of all the molecules were retrieved from Pubchem, 
chemical structure followed by 2D structure cleaning, 3D optimization 
and viewing. Molecular docking study of molecules against Lanosterol 14 
α-demethylase was carried out. Docking simulation was done using 
AutoDock®suite as a molecular-docking tool [15]. Default optimization 
parameters were used Lamarckian Genetic Algorithm was used with a 
population size of 150 dockings. Autodock® tools generated 60 possible 
binding conformations, i.e. 60 runs for each docking by using Genetic 
Algorithm (GALS) searches. The grid box used for specifying the search 
space was set at 60 × 60 × 60 centered on of Protein with a default grid 
point spacing of 0.375 Å. Autogride was used to obtain pre-calculated 
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grid maps. 25.84083, 10.02083 and 9.119833 were used as x, y and z co-
ordinate during Grid preparation. Docking of molecules with the 
predicted structure on Lanosterol 1,4α-demethylase was done. After 
completion of docking, most suitable conformations were chosen based 
on the lowest docked energy. Selected conformations were analyzed by 
Autodock® tool and Discovery studio® [14, 15].  
 



















Excellent binding 1.  Ketoconazole LYS143 HZ3…. N4 1 -11.85 -0.31 
2.  Hesperidin TYR118 OH…. H20 5 -9.76 -0.2 
GLY307 O…. H31 
THR311 HG1…. O15 
LYS143 HZ3…. O6 
TYR132 HH…. O3 
3.  Quinine THR311 HG1…. O2 2 -9.2 -0.06 
ILE471 HN…. O1 
4.  Riboflavin ILE471 HN…. O1 4 -8.56 -0.44 
HIS468 H20…. O 
LYS143 HZ3…. O4 
TYR132 OH…. H12 
5.  Piperine LYS143 OH…. O3 2 -8.54 -0.09 
TYR132 HZ3…. O2 
6.  Rutin-trihydrate HIS468 O…. H29 3 -8.52 -0.42 
TYR132 HH…. O6 
TYR132 OH…. H20 
7.  Caryophyllene-oxide LYS143 HZ3…. O1 1 -7.66 -0.28 
8.  Quercetin HIS468 O…. H9 5 -7.54 -0.36 
GLY307 O…. H8 
THR311 HG1…. O5 
LYS143 HZ3…. O6 
TYR132 OH…. H10 
Good 9.  Betaionone LYS143 HZ3…. O1 1 -6.95 -0.39 
10.  Alpha-bisabolol ILE471 HN…. O1 1 -6.91 -0.08 
11.  Fluconazole ARG469 O…. H5 2 -6.82 -0.33 
LYS143 HZ3…. N4 
12.  Indole-3-butyric-acid LYS143 HZ3…. O2 1 -6.73 -0.34 
13.  Geranylgeranoil LYS143 HZ3…. O1 1 -6.67 -0.25 
14.  Geranylacetate LYS143 HZ3…. O2,O1 1 -6.08 -0.36 
15.  Farnesol HIS468 O…. H26 2 -6.06 -0.15 
LYS143 HZ3…. O1 
16.  Caffeine ILE471 HN…. O2 1 -6.02 -0.11 
Medium 
 
17.  Caffeic-acid GLY307 O…. H6 3 -5.79 -0.24 
THR311 HN…. O2 
MET306 O…. H7 
18.  Citral LYS143 HZ3…. O1 1 -5.76 -0.35 
19.  Cinnamic-acid LYS143 HZ3…. O2 1 -5.75 -0.43 
20.  Carvacrol GLN479 OE1…. H14 2 -5.67 -0.05 
GLN479 HE21…. O1 
21.  Citronellol LYS143 HZ3…. O1 1 -5.48 -0.32 
22.  Geraniol HIS468 O…. H18 1 -5.48 -0.26 
23.  Carvone LYS143 HZ3…. O1 1 -5.47 -0.35 
24.  1-8,cineole SER378 O…. H18 1 -5.45 -0.04 
25.  Salicylic-acid HIS468 O…. H5 2 -5.44 -0.49 
LYS143 HZ3…. O3 
26.  Borneol LYS143 HZ3…. O1 1 -5.43 -0.40 
27.  Menthol ILE471 HN…. O1 1 -5.38 -0.03 
28.  Eugenol HIS468 O…. H10 2 -5.38 -0.19 
LYS143 HZ3…. O1 
29.  Methyleugenol HIS468 O…. O2 2 -5.36 -0.16 
LYS143 HZ3…. O1 
 
 
30.  Isopulegol ILE304 O…. H13 1 -5.32 -0.03 
31.  1-4,cineole ILE304 O…. O1 1 -5.31 -0.05 
32.  Nerol LYS143 HZ3…. O1 2 -5.29 -0.26 
HIS468 O…. H18 
33.  Alpha-thujone LYS143 HZ3…. O1 1 -5.22 -0.24 
34.  Sabinene-hydrate SER378 O……H18 1 -5.22 -0.05 
35.  Thymol ILE304 O…. H14 1 -5.16 -0.06 
36.  Cinnamaldehyde LYS143 HZ3…. O1 1 -5.1 -0.22 
37.  Betacitronellol HIS468 O…. H14 1 -5.03 -0.14 
38.  Nicotinic-acid LYS143 HZ3…. O2 1 -4.92 -0.4 
39.  Indole HIS468 O…. H1 1 -4.81 -0.06 
40.  1-tetradecanol HIS468 O…. H30 2 -4.77 -0.38 
LYS143 HZ3…. O1 
41.  Ascorbic-acid HIS468 O…. H7 4 -4.76 -0.49 
TYR132 OH…. H8 
HIS468 O…. H5 
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LYS143 HZ3…. O6 
42.  Salicylaldehyde TYR132 OH…. H6 2 -4.68 -0.37 
LYS143 HZ3…. O2 
43.  Guaiacol LYS143 HZ3…. O2 2 -4.49 -0.33 
HIS468 O…. H8 
44.  Trichloroacetic-acid LYS143 HZ3…. O2 1 -4.43 -0.038 
45.  2-phenylethanol MET306 O…. H10 2 -4.40 -0.08 
THR311 HN…. O1 
46.  Piperidine TYR257 OH…. H1 1 -4.0 -0.02 
47.  Allyl-alcohol GLU115 OE1…. H6 3 -3.28 
 
-0.35 
 ASN136 HD22…. O1 
HIS468 HE2…. O1 
48.  Allyl-isothiocynate LYS143 HZ3…. N1 1 -3.0 -0.12 
No hydrogen 
formation 
49.  Gamma-cadinene - - -- -7.31 -0.01 
50.  Beta-elemene - - -- -5.93 -0.01 
51.  Terpinolene - - -- -5.55 -0.01 
52.  Beta-pinene - - -- -5.33 0.0 
53.  Alpha-pinene - - -- -5.32 0.0 
54.  Eucalyptol - - -- -5.32 0.0 
55.  Limonene - - -- -5.31 0.0 
56.  Alpha-phellandrene - - -- -5.23 0.0 
57.  Camphene - - -- -5.13 0.0 
58.  Myrcene - - -- -4.88 0.0 
59.  Sabinene - - -- -4.77 -0.01 
60.  P-cymene - - -- -4.77 0.0 
 
RESULTS  
Homology modeling and molecular docking against lanosterol 
14 α-demethylase  
Molecular docking of sixty plant molecules with the best predicted 
model of Lanosterol 14 α-demethylase CYP51 protein was 
successfully done using Autodock 1.5.6 cr2™. When validation was 
done by Procheck, it found that 90.2 % residues are in most favored 
regions [A, B, L]. Docking results of sixty plant molecules with 
Lanosterol 14 α-demethylase was calculated on the basis of RMSD 
values and compared with that of standard drugs (Fluconazole and 
Ketoconazole). The results of all the sixty docked molecules are 
listed in table 1. Docked plant molecules showed binding energy 
with a range of-9.76 to-3.0 kcal/mol. The lowest binding energy or 
more negative energy was considered to be the best docking results. 
After docking 60 best runs having the lowest binding energy was 
chosen as best candidates for building a complex of Ligand and 
Lanosterol 14 α-demethylase protein. From the best-chosen 
candidates, seven plant molecules were shown to have excellent 
binding energy, namely Hesperidin, Quinine, Riboflavin, Piperine, 
Rutin-trihydrate, Caryophyllene-oxide and Quercetin (table 1). 
Hesperidin showed to minimum binding energy-9.76 kcal/mol and 
formation of a hydrogen bond at TYR118, GLY307, THR311, LYS143 
and TYR132 residues of protein (fig. 1). Quinine formed two 
hydrogen bonds at TYR132 AND ILE471 with binding energy 9.2 
Kcal/mol (fig. 2). Riboflavin showed the formation of four hydrogen 
bonds with ILE471, HIS468, LYS143 and TYR132 having binding 
energy-8.56 kcal/mol (fig. 3). Piperine was found to form two 
hydrogen bonds with LYS143 and TYR132 with the-8.54 kcal/mol 
binding energy (fig. 4). Rutin-trihydrate was observed to bind with 
HIS468, TYR132 and TYR132 by three hydrogen bonds with binding 
energy-8.52 kcal/mol (fig. 5). Caryophyllene-oxide formed one 
hydrogen bond LYS143 amino acid residue with binding energy-7.66 
kcal/mol (fig. 6). Quercetin formed five hydrogen bonds with 
HIS468, GLY307, THR311, LYS143 and TYR143, having binding 
energy-7.54 kcal/mol (fig. 7). Betaionone, Alpha-bisabolol, 
Geranylgeranoil, Indole-3-butyric acid and Geranylacetate showed 
the formation of one-one hydrogen bonds with amino acid residue 
LYS143, ILE143, ILE471, LYS143 and LYS143 with binding energy-
6.95,-6.91,-6.67,-6.73 and-6.08 kcal/mol respectively (fig. 8-12). 
Farnesol formed two hydrogen bonds with amino acid residues of-
6.06 kcal/mol (fig. 13). Caffeine formed H-bond with ILE471 having 
binding energy-6.02 kcal/mol (fig. 14). Caffeic-acid formed three 
hydrogen-bonds with GLY307, THR311 and MET306 by binding 
energy-5.79 kcal/mol (fig. 15). Citral and Cinnamic acid showed a 
hydrogen bond with LYS143 and LYS143 with binding energy of-
5.76 and-5.75 kcal/mol (fig. 16, 17). Carvacrol was found to form 
two hydrogen-bonds with GLN479 and GLN479 having binding 
energy-5.67 kcal/mol (fig. 18). Citronellol, Geraniol, Carvone and 1, 
8 Cineole showed hydrogen bond with LYS143, HIS468, LYS143 and 
SER378 with binding energy-5.48,-5.48,-5.47 and-5.45 kcal/mol (fig. 
19-22). Salicylic-acid was found to form two hydrogen bonds with 
HIS468 and LYS143 with binding energy of-5.44 kcal/mol (fig. 23) 
Borneol and Menthol were found to form one–one hydrogen bond 
with LYS143 and ILE471 amino acid residues with-5.43 and-5.38 
kcal/mol binding energy respectively (fig. 24-25). Eugenol was found 
to form two hydrogen bonds HIS468 and LYS143, with-5.38 kcal/mol 
binding energy (fig. 26). Methyleugenol was formed two hydrogen 
bonds with HIS468 and LYS143 having-5.38 kcal/mol (fig. 27). 
Isopulegol is shown to form hydrogen bond with amino acid residue 
ILE304 with binding energy of-5.36 kcal/mol (fig. 28). 1, 4 Cineole 
form hydrogen bond with ILE304 with-5.31kcal/mol binding energy 
(fig. 29). Nerol formed a two hydrogen bond LYS143 and HIS468 
having-5.29 kcal/mol (fig. 30). Seven molecules namely Alpha-thujone, 
Sabinene-hydrate, Thymol, Cinnamaldehyde, Betacitronellol, 
Nicotinic-acid and Indole was found to form a one-one hydrogen 
bond with amino acid residues, LYS143, SER378, ILE304, LYS143, 
HIS468, LYS143, LYS143 and HIS468 respectively, with having 
binding energy of-5.22,-5.22,-5.16,-5.1,-5.03,-4.92 and-4.81 kcal/mol 
(fig. 31-37). 1-tetradecanol found to form two hydrogen bonds 
HIS468 and LYS143 with amino acid residues having-4.77 kcal/mol 
binding energy (fig. 38). Ascorbic-acid formed four hydrogen bond 
with HIS468, TYR132, HIS468, and LYS132 having-4.76 kcal/mol 
(fig. 39). Salicylaldehyde formed two hydrogen bonds TYR132 and 
LYS143 having-4.68 kcal/mol binding energy (fig. 40). Guaiacol 
formed two hydrogen bonds with LYS143 and HIS468 with binding 
energy of-4.49 kcal/mol (fig. 41). Trichloroacetic-acid forms a 
hydrogen bond with LYS143 amino acid residue with-4.43 kcal/mol 
binding energy (fig. 42). 2-Phenylethanol formed two hydrogen 
bonds with MET306 and THR311 were having-4.40 kcal/mol 
binding energy (fig. 43). Piperidine was found to form hydrogen 
bond with TYR257 having-4.0 kcal/mol binding energy (fig. 44). 
Allyl-alcohol formed three hydrogen bonds GLU15, ASN136 and 
HIS468 having binding energy-3.28 kcal/mol (fig. 45). Allyl-
isothiocynate formed one hydrogen bond with LYS143 with binding 
energy 3.0 kcal/mol (fig. 46).  
Fluconazole and Ketoconazole were taken as standard drugs, which 
are widely used as antifungal agents. Fluconazole formed two 
hydrogen bonds ARG469 and LYS143, having-6.82 kcal/mol binding 
energy (fig. 47). Ketoconazole also formed hydrogen bond with 
LYS143 with amino acid residues having-11.85 kcal/mol binding 
energy with protein (fig. 48). 
However, Rest of the molecules did not form hydrogen bond with amino 
acid residues these molecules are. Alpha-pinene, Beta-pinene, 
Camphene, Beta-elemene, Alpha-phellandrene, Eucalyptol, Myrcene, P-
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cymene, Sabinene, Terpinolene, Gamma, cadinene, Limonene. Docking 
results of sixty plant molecules with Lanosterol 14 α-demethylase was 
compared to Ketoconazole on the basis of binding residue LYS143. The 
comparison shows that 14 molecules Caryophyllene-oxide, Betaionone, 
Indole-3-butyric-acid, Geranylgeranoil, Geranylacetate, Citral, Cinnamic-
acid, Citronellol, Carvone, Borneol, Alpha-thujone, Cinnamaldehyde, 
Nicotinic-acid, and Allyl-alcohol interacted with LYS143 of Lanosterol 14 
α-demethylase similar to that of Ketoconazole. 
  
Fig. 1: Docked complex showing hesperidin with lanosterol 14 α-
demethylase 
 
Fig. 2: Docked complex showing quinine with lanosterol 14 α-
demethylase 
 
Fig. 3: Docked complex showing Riboflavin with lanosterol 14 α-
demethylase 
 
Fig. 4: Docked complex showing Piperine with lanosterol 14 α-
demethylase 
 
Fig. 5: Docked complex showing Rutin-trihydrate with lanosterol 
14 α-demethylase 
 
Fig. 6: Docked complex showing caryophyllene-oxide with lanosterol 
14 α-demethylase 
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Fig. 7: Docked complex showing Quercetin with lanosterol 14 α-
demethylase 
 
Fig. 8: Docked complex showing Betaionone with lanosterol 14 α-
demethylase 
 
Fig. 9: Docked complex showing alpha-bisabolol with lanosterol 
14 α-demethylase 
 
Fig. 10: Docked complex showing geranyl geranoil with lanosterol 
14 α-demethylase 
 
Fig. 11: Docked complex showing Indole-3-butyric acid with 
lanosterol 14 α-demethylase 
 
Fig. 12: Docked complex showing Geranylacetate with lanosterol 14 
α-demethylase 
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Fig. 13: Docked complex showing Farnesol with lanosterol 14 α-
demethylase 
 
Fig. 14: Docked complex showing caffeine with lanosterol 14 α-
demethylase 
 
Fig. 15: Docked complex showing caffeic-acid with lanosterol 14 
α-demethylase 
 
Fig. 16: Docked complex showing citral with lanosterol 14 α-
demethylase 
 
Fig. 17: Docked complex showing cinnamic-acid with lanosterol 
14 α-demethylase 
 
Fig. 18: Docked complex showing carvacrol with lanosterol 14 α-
demethylase 
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Fig. 19: Docked complex showing citronellol with lanosterol 14 α-
demethylase 
 
Fig. 20: Docked complex showing geraniol with lanosterol 14 α-
demethylase 
 
Fig. 21: Docked complex showing carvone with lanosterol 14 α-
demethylase 
 
Fig. 22: Docked complex showing 1-8 cineole with lanosterol 14 α-
demethylase 
 
Fig. 23: Docked complex showing Salicylic-acid with lanosterol 14 
α-demethylase 
 
Fig. 24: Docked complex showing Borneol with lanosterol 14 α-
demethylase 
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Fig. 25: Docked complex showing Menthol with lanosterol 14 α-
demethylase 
 
Fig. 26: Docked complex showing eugenol with lanosterol 14 α-
demethylase 
 
Fig. 27: Docked complex showing Methyleugenol with lanosterol 
14 α-demethylase 
 
Fig. 28: Docked complex showing Isopulegol with lanosterol 14 α-
demethylase 
 
Fig. 29: Docked complex showing 1,4-cineole with lanosterol 14 
α-demethylase 
 
Fig. 30: Docked complex showing nerol with lanosterol 14 α-
demethylase 
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Fig. 31: Docked complex showing Alpha-thujone with lanosterol 
14 α-demethylase 
 
Fig. 32: Docked complex showing Sabinene-hydrate with lanosterol 
14 α-demethylase 
 
Fig. 33: Docked complex showing thymol with lanosterol 14 α-
demethylase 
 
Fig. 34: Docked complex showing cinnamaldehyde with lanosterol 
14 α-demethylase 
 
Fig. 35: Docked complex showing betacitronellol with lanosterol 
14 α-demethylase 
 
Fig. 36: Docked complex showing nicotinic-acid with lanosterol 14 α-
demethylase 
Karuppayil et al. 
Int J App Pharm, Vol 12, Special Issue 4, 2020, 18-30 
International Conference On Cancer Biology: Basic Science to Translational Research (CBTR 2020)                                                                      | 27 
 
Fig. 37: Docked complex showing Indole with lanosterol 14 α-
demethylase 
 
Fig. 38: Docked complex showing 1-tetradecanol with lanosterol 14 
α-demethylase 
 
Fig. 39: Docked complex showing ascorbic-acid with lanosterol 14 
α-demethylase 
 
Fig. 40: Docked complex showing Salicylaldehyde with lanosterol 14 
α-demethylase 
 
Fig. 41: Docked complex showing guaiacol with lanosterol 14 α-
demethylase 
 
Fig. 42: Docked complex showing trichloroacetic-acid with 
lanosterol 14 α-demethylase 
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Fig. 43: Docked complex showing 2-phenoylethanol with 
lanosterol 14 α-demethylase 
 
Fig. 44: Docked complex showing piperidine with lanosterol 14 α-
demethylase 
 
Fig. 45: Docked complex showing allyl-alcohol with lanosterol 14 
α-demethylase 
 
Fig. 46: Docked complex showing allyl-isothiocynate with lanosterol 
14 α-demethylase 
 
Fig. 47: Docked complex showing fluconazole with lanosterol 14 
α-demethylase 
 
Fig. 48: Docked complex showing ketoconazole with lanosterol 14 α-
demethylase 
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DISCUSSION 
Ergosterol biosynthesis is considered as an antifungal target 
because ergosterol is vital for the survival of fungal cell [16-18]. 
Lanosterol 14 α-demethylase catalyses the conversion of lanosterol 
to ergosterol [18]. For example, Fluconazole can inhibit ergosterol 
biosynthesis by inhibiting the activity of lanosterol 14 α-
demethylase enzyme. Amphoterin B can inhibit ergosterol 
polymerization and creates hole in the ergosterol membrane and 
leads to the leak of ions from the cell [18]. These two drugs are very 
important, however, these drugs has various side effects. For 
example, Amphoterin B has a serious nephrotoxicity effect, while 
Fluconazole is fungi static and can affect the estrogen synthesis [19]. 
Drug resistance and mutation in ergosterol biosynthetic gene ERG11 
is also reported [20]. There are few other drugs which are known to 
be ergosterol inhibitors like Ketoconazole. Considering the side 
effect of these molecules, there some studies where people have 
explored the potential of plant molecules as ergosterol inhibitors. 
Rajput and Karuppayil (2013) has studied the efficacy of twenty-five 
plant molecules, Cinnamaldehyde, Piperidine, Indole, 
Furfuraldehyde, Citral, Beta-Pinene, Salicylic Acid, Guaiacol, Cymene, 
Caffeine, Camphene, Citronellol, Geraniol, Geranylacetate, Alpha-
Pinene, Carvone, Linalool, Thujone, Bisabolol, Jasmonate, Isopulegol, 
Limonene, 1,4-Cineole, 1,8-Cineole, and Menthol, on the synthesis of 
ergosterol in the human pathogen and Candida albicans [21]. Out of 
25 molecules studied six molecules, they have identified as 
inhibitors of ergosterol. But their study has not defined what these 
molecules targeted in ergosterol biosynthetic pathway. Ahmad et al., 
(2011) studied the Fungicidal activity of Thymol and Carvacrol; they 
found that both these molecules showed fungicidal activity by 
inhibiting ergosterol biosynthesis [22]. Prasanna et al., (2014) have 
studied 25 molecules which are found in plants used in Siddha 
medicine, Aurantiamide Acetate, B-Sitosterol, Kaempferol, Clitorin, 
Mauritianin, Nicotiflorin, Vitexdoin A, Vitedoamine B, Vitexin, 
Betulinic Acid, Oleanolic Acid, Caryophyllene Oxide, Daturamalakin 
B, Hyoscyamine, Phenowithanolide, Withametelin, Scopolamine, 1, 
6-Heptadiene-3, 5-Dione, 5-Hydroxyl-1,7-Bis 4, 6-Heptadiene-3-One, 
Tetrahydroxycurcumin, Curcumin, Demethoxycurcumin, 
Bisdemethoxy-curcumin including Fluconazole and Ketoconazole 
and they have given the binding energy of these molecules. Their 
study revealed that clitorin, mauritianin, and kaempferol bound to 
lanosterol 14 a-demethylase by hydrogen bonding and hydrophobic 
interaction [23].  
Considering the efficacy of plant molecules as inhibitors of 
ergosterol biosynthesis, we wanted to know whether these plant 
molecules may interact with lanosterol 14 α-demethylase enzyme or 
not. Our study suggests that out of sixty plant molecules, forty-eight 
molecules are showing binding with lanosterol 14 α-demethylase 
(table 1). Even though molecules like Alpha-pinene, Beta-pinene, 
Camphene, and Limonene are showing ergosterol inhibition in the 
study of Rajput and Karuppayil (2013), in our study they were not 
found to be interacting with lanosterol 14 α-demethylase. So it 
means that they may have different targets other than lanosterol 
14α-demethylase (table 1). 
We compared our docking results with Ketoconazole to find the 
similarity among our molecules and standard drug. Interestingly, we 
found that out of 48 docked molecules, 14 molecules Caryophyllene-
oxide, Betaionone, Indole-3-butyric-acid, Geranylgeranoil, 
Geranylacetate, Citral, Cinnamic-acid, Citronellol, Carvone, Borneol, 
Alpha-thujone, Cinnamaldehyde, Nicotinic-acid, and Allyl-alcohol 
showed similar interacting residue LYS143 as that of Ketoconazole 
(table 2). Out of 14 molecules, Caryophyllene-oxide, Betaionone, 
Indole-3-butyric-acid, Geranylgeranoil, Geranylacetate, Citral, 
Cinnamic-acid, Citronellol, Carvone, Borneol, Alpha-thujone, 
Cinnamaldehyde, Nicotinic-acid, and Allyl-alcohol, six molecules are 
already known to inhibit ergosterol biosynthesis. Caryophyllene-
oxide is known to inhibit the ergosterol biosynthesis [21, 23]. 
Geranylacetate, Citral, Citronellol, Carvone, and Cinnamaldehyde are 
known to have inhibitory affect against lanosterol 14α-demethylase 
[14]. The above data supports our hypothesis that as Ketoconazole 
interacting to lanosterol 14α-demethylase by LYS143 amino acid 
and 14 molecules have same binding residue may have similar mode 
of action. Rest the of eight molecules interacting via the similar 
LYS143 residue as that of Ketoconazole may also have same 
ergosterol inhibiting effect as that of Ketoconazole and may be used 
as potent antifungal drugs. 
More than 300 million people are reported to suffer from a serious 
fungal infections resulting in over 1,350,000 deaths [24]. 
Importance of fungal infections has led to a remarkable rise in the 
application of antifungal agents for the treatment and prevention of 
infection. Regrettably, the treatment options are highly limited, as 
there are few chemical classes represented by existing antifungal 
drugs [25]. On the contrary, azole groups of drugs are most 
commonly prescribed drugs for the treatment of Candida albicans 
infections for more than 30 y although prolonged use of any drugs, 
causes drug resistance [26-30].  
In this study out of sixty plant molecules 12 plant molecules (Alpha-
pinene, Beta-pinene, Camphene, Beta_elemene, Alpha_phellandrene, 
Eucalyptol, Myrcene, P-cymene, Sabinene, Terpinolene, Gamma-
cadinene, and Limonene) has shown no hydrogen bond formation 
with the active site of lanosterol 14 α-demethylase (table 1).  
Previous studies state that to interact with ligand, there must have 
some means of interaction between molecule and protein like 
hydrogen bond formation [31]. Those 48 plant molecules showing 
excellent and good binding affinities may inhibit the activity of 
lanosterol 14 α-demethylase by binding at its active site. These 
results may need to be confirmed ergosterol assay. 
CONCLUSION 
Molecular Docking studies revealed that out of 60 molecules 48 
molecules has shown good binding affinity with lanosterol 1, 4α-
demethylase. These molecules may inhibit the activity of lanosterol 
14 α-demethylase and thereby inhibit the ergosterol synthesis in 
Candida albicans. 14 molecules have shown similar interactions as 
that of Ketoconazole since they are binding at LYS143. On the other 
hand, our study also revealed that 12 molecules did not form any 
hydrogen bond with the predicted model of lanosterol 14 α-
demethylase; however, it doesn’t mean that these 12 molecules may 
have no activity, as previous study shows these molecules also have 
antifungal activity their target may be different from that of 
lanosterol 14 α-demethylase enzyme. From the present study, we 
conclude that lanosterol 14 α-demethylase is a good target for 
antifungal drug,s. Using our 48 docked molecules one can develop 
new antifungal/potential drugs which are the inhibitors of 
lanosterol 14 α-demethylase of Candida albicans. There is a need for 
in vitro and in vivo studies to cofirm the efficacy of these molecules 
against Candida albicans pathogenesis. 
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